Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 7Phase 3 5Phase 1/2 4Phase 2/3 2

Status

Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Lymphoid 1Breast 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 95Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × 1-dodecylpyridoxal × Gynecologic × Clear all
NCT07564141 2026-06-03

RAINFOLâ„¢-07

Genmab

Phase 3 Not yet recruiting
688 enrolled
Gynecologic

Ovarian Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

Pfizer

Phase 3 Completed
566 enrolled 40 charts
Gynecologic

Ovarian Neoplasms

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

AGO Research GmbH

Phase 3 Terminated
9 enrolled
Gynecologic

Ovarian Neoplasms

NCT01837251 2021-07-13

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

AGO Research GmbH

Phase 3 Completed
682 enrolled
Gynecologic

Ovarian Neoplasms

NCT01281254 2017-12-02

TRINOVA-2

Amgen

Phase 3 Terminated
223 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡